Links Between Semaglutide, a Glucagon-Like Peptide-1 Drug, and Irregular Heartbeats: A Review of Overlapping Studies

Glucagon-like peptide-1 receptor agonists, particularly semaglutide, are associated with lower rates of incident atrial fibrillation.

• Multiple meta-analyses indicate that GLP-1 receptor agonists may reduce the occurrence of new atrial fibrillation.
• Semaglutide is specifically noted for its potential impact on lowering atrial fibrillation incidents.
• These analyses suggest that GLP-1 receptor agonists could also decrease the recurrence of atrial fibrillation after ablation procedures.
• The reviews often rely on overlapping trial data, indicating a need for distinct studies to confirm these associations.

Simplified